Try our beta test site
75 studies found for:    hvtn
Show Display Options
Rank Status Study
1 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
2 Completed Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant;   Other: Sodium chloride
3 Completed Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
4 Recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
5 Unknown  Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: AIDSVAX B/E;   Biological: Placebo for ALVAC-HIV;   Biological: Placebo for AIDSVAX B/E;   Biological: Hepatitis B vaccine;   Biological: Tetanus toxoid vaccine;   Biological: Placebo for hepatitis B vaccine;   Biological: Placebo for tetanus vaccine
6 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
7 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
8 Completed Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Lentivirus Infections;   Retroviridae Infections;   RNA Virus Infections;   Virus Diseases;   Sexually Transmitted Diseases, Viral;   Sexually Transmitted Diseases;   Immunologic Deficiency Syndromes;   Immune System Diseases;   Slow Virus Diseases
Interventions: Procedure: Circumcision;   Procedure: Flexible sigmoidoscopy
9 Completed A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
Condition: HIV Infections
Intervention: Other: Observation
10 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
11 Active, not recruiting A Safety and Immune Response Study of 2 Experimental HIV Vaccines
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: Bivalent Subtype C gp120/MF59®;   Biological: ALVAC-HIV (vCP2438) Placebo;   Biological: Bivalent gp120/MF59® Placebo
12 Completed A Study to Prepare for Future HIV Vaccine Studies
Condition: HIV Infections
Intervention:
13 Completed Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
Condition: HIV Infections
Interventions: Biological: MRKAd5 HIV-1 gag/pol/nef;   Other: Placebo
14 Completed Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: SAAVI DNA-C2 vaccine;   Biological: SAAVI MVA-C vaccine;   Biological: Placebo
15 Completed Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123;   Biological: NYVAC-HIV-PT1;   Biological: NYVAC-HIV-PT4;   Biological: AIDSVAX® B/E;   Biological: Placebo for DNA/NYVAC;   Biological: Placebo for AIDSVAX(R) B/E
16 Completed Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
Condition: HIV Infections
Interventions: Biological: PennVax B;   Biological: IL-12;   Biological: IL-15
17 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
18 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
19 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
20 Completed Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-B;   Biological: IL-12 DNA plasmids

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.